Retraction: Molecular mechanism of thiazolidinedione-mediated inhibitory effects on osteoclastogenesis (PLoS ONE (2014) 9: 7 (e102706) DOI: 10.1371/journal.pone.0102706);Molecular mechanism of thiazolidinedione-mediated inhibitory effects on osteoclastogenesis

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Zhao, Dongfeng ^a,b   Shi, Zhenqi ^b   Warriner, Amy H ^c   Qiao, Ping ^b   Hong, Huixian ^b   Wang, Yongjun ^a   Feng, Xu ^b  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CARBONATE DEHYDRATASE II; CATHEPSIN K; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; PIOGLITAZONE; PROTEIN C FOS; ROSIGLITAZONE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC1; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2,4-THIAZOLIDINEDIONE; ACID PHOSPHATASE; ISOENZYME; TARTRATE-RESISTANT ACID PHOSPHATASE;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION; IN VITRO STUDY; INHIBITION KINETICS; MACROPHAGE; MALE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; OSTEOCLAST GENE; OSTEOCLASTOGENESIS; OSTEOLYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; BONE MARROW; C57BL MOUSE; CELL DIFFERENTIATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; OSTEOCLAST; SIGNAL TRANSDUCTION;

ACID PHOSPHATASE; ANIMALS; BONE MARROW; CARBONIC ANHYDRASE II; CATHEPSIN K; CELL DIFFERENTIATION; FEMALE; GENE EXPRESSION REGULATION; ISOENZYMES; MALE; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-FOS; RANK LIGAND; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES;

EID: 84904479734     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0229392     Document Type: Erratum

References (58)

1. Shaw JE, Sicree RA, Zimmet PZ (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87: 4-14.
2. Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, et al. (2010) Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 87: 293-301.
3. Krishnaswami A, Ravi-Kumar S, Lewis JM (2010) Thiazolidinediones: a 2010 perspective. Perm J 14: 64-72.
4. Krentz AJ, Bailey CJ (2005) Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 65: 385-411. (Pubitemid 40227460)
5. Reginato MJ, Lazar MA (1999) Mechanisms by which Thiazolidinediones Enhance Insulin Action. Trends Endocrinol Metab 10: 9-13. (Pubitemid 29288704)
6. Tontonoz P, Spiegelman BM (2008) Fat and beyond: the diverse biology of PPARgamma. Annual review of biochemistry 77: 289-312.
7. Kim HI, Ahn YH (2004) Role of peroxisome proliferator-activated receptor-gamma in the glucose-sensing apparatus of liver and beta-cells. Diabetes 53 Suppl 1: S60-65.
8. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, et al. (1999) Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402: 880-883.
9. Tontonoz P, Hu E, Spiegelman BM (1994) Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79: 1147-1156.
10. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM (1998) PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93: 241-252. (Pubitemid 28180857)
11. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, et al. (2001) A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7: 161-171. (Pubitemid 32162909)
12. Jiang C, Ting AT, Seed B (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82-86. (Pubitemid 28079219)
13. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391: 79-82. (Pubitemid 28079218)
14. Lehrke M, Lazar MA (2005) The many faces of PPARgamma. Cell 123: 993-999.
15. Moseley KF (2012) Type 2 diabetes and bone fractures. Curr Opin Endocrinol Diabetes Obes 19: 128-135.
16. Betteridge DJ (2011) Thiazolidinediones and fracture risk in patients with Type 2 diabetes. Diabet Med 28: 759-771.
17. Bazelier MT, de Vries F, Vestergaard P, Herings RM, Gallagher AM, et al. (2013) Risk of fracture with thiazolidinediones: an individual patient data meta-analysis. Front Endocrinol (Lausanne) 4: 11.
18. Mabilleau G, Chappard D, Basle MF (2011) Cellular and molecular effects of thiazolidinediones on bone cells: a review. Int J Biochem Mol Biol 2: 240-246.
19. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, et al. (2002) Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 143: 2376-2384. (Pubitemid 34521584)
20. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, et al. (2005) Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146: 1226-1235. (Pubitemid 40289310)
21. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B (2004) Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145: 401-406. (Pubitemid 38094536)
22. Soroceanu MA, Miao D, Bai XY, Su H, Goltzman D, et al. (2004) Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 183: 203-216. (Pubitemid 40124657)
23. Mabilleau G, Mieczkowska A, Edmonds ME (2010) Thiazolidinediones induce osteocyte apoptosis and increase sclerostin expression. Diabet Med 27: 925-932.
24. Okazaki R, Toriumi M, Fukumoto S, Miyamoto M, Fujita T, et al. (1999) Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology 140: 5060-5065.
25. Chan BY, Gartland A, Wilson PJ, Buckley KA, Dillon JP, et al. (2007) PPAR agonists modulate human osteoclast formation and activity in vitro. Bone 40: 149-159. (Pubitemid 44839345)
26. Hounoki H, Sugiyama E, Mohamed SG, Shinoda K, Taki H, et al. (2008) Activation of peroxisome proliferator-activated receptor gamma inhibits TNF-alpha-mediated osteoclast differentiation in human peripheral monocytes in part via suppression of monocyte chemoattractant protein-1 expression. Bone 42: 765-774.
27. Hassumi MY, Silva-Filho VJ, Campos-Junior JC, Vieira SM, Cunha FQ, et al. (2009) PPAR-gamma agonist rosiglitazone prevents inflammatory periodontal bone loss by inhibiting osteoclastogenesis. International immunopharmacology 9: 1150-1158.
28. Yang CR, Lai CC (2010) Thiazolidinediones inhibit TNF-alpha-mediated osteoclast differentiation of RAW264.7 macrophages and mouse bone marrow cells through downregulation of NFATc1. Shock 33: 662-667.
29. Jiang M, Lu S, Wu L, Liu J, Cheng P, et al. (2010) [Effect of pioglitazone on receptor activator of nuclear factor-kappa B expression in osteoclast from RAW264.7 cells]. Zhonghua Yi Xue Za Zhi 90: 2282-2285.
30. Cho ES, Kim MK, Son YO, Lee KS, Park SM, et al. (2012) The effects of rosiglitazone on osteoblastic differentiation, osteoclast formation and bone resorption. Mol Cells 33: 173-181.
31. Wan Y, Chong LW, Evans RM (2007) PPAR-gamma regulates osteoclastogenesis in mice. Nature medicine 13: 1496-1503.
32. Wu H, Li L, Ma Y, Chen Y, Zhao J, et al. (2013) Regulation of selective PPARgamma modulators in the differentiation of osteoclasts. J Cell Biochem 114: 1969-1977.
33. Teitelbaum SL (2007) Osteoclasts: what do they do and how do they do it? Am J Pathol 170: 427-435.
34. Feng X, McDonald JM (2011) Disorders of bone remodeling. Annu Rev Pathol 6: 121-145.
35. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423: 337-342. (Pubitemid 40852708)
36. Feng X (2005) Regulatory roles and molecular signaling of TNF family members in osteoclasts. Gene 350: 1-13.
37. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, et al. (2002) Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3: 889-901. (Pubitemid 35460788)
38. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, et al. (1994) c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266: 443-448.
39. Cappellen D, Luong-Nguyen NH, Bongiovanni S, Grenet O, Wanke C, et al. (2002) Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator of NFkappa B. J Biol Chem 277: 21971-21982. (Pubitemid 34952352)
40. Rho J, Altmann CR, Socci ND, Merkov L, Kim N, et al. (2002) Gene expression profiling of osteoclast differentiation by combined suppression subtractive hybridization (SSH) and cDNA microarray analysis. DNA Cell Biol 21: 541-549.
41. Xu D, Wang S, Liu W, Liu J, Feng X (2006) A novel receptor activator of NF-kappaB (RANK) cytoplasmic motif plays an essential role in osteoclastogenesis by committing macrophages to the osteoclast lineage. The Journal of biological chemistry 281: 4678-4690. (Pubitemid 43847727)
42. Liu J, Wang S, Zhang P, Said-Al-Naief N, Michalek SM, et al. (2009) Molecular mechanism of the bifunctional role of lipopolysaccharide in osteoclastogenesis. The Journal of biological chemistry 284: 12512-12523.
43. Zou W, Bar-Shavit Z (2002) Dual modulation of osteoclast differentiation by lipopolysaccharide. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 17: 1211-1218.
44. Huang W, O'Keefe RJ, Schwarz EM (2003) Exposure to receptor-activator of NFkappaB ligand renders pre-osteoclasts resistant to IFN-gamma by inducing terminal differentiation. Arthritis Res Ther 5: R49-59.
45. Cheng J, Liu J, Shi Z, Jules J, Xu D, et al. (2012) Molecular mechanisms of the biphasic effects of interferon-gamma on osteoclastogenesis. J Interferon Cytokine Res 32: 34-45.
46. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, et al. (2000) TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. The Journal of clinical investigation 106: 1481-1488. (Pubitemid 32038586)
47. Jules J, Shi Z, Liu J, Xu D, Wang S, et al. (2010) Receptor activator of NF-{kappa}B (RANK) cytoplasmic IVVY535-538 motif plays an essential role in tumor necrosis factor-{alpha} (TNF)-mediated osteoclastogenesis. The Journal of biological chemistry 285: 37427-37435.
48. Jules J, Zhang P, Ashley JW, Wei S, Shi Z, et al. (2012) Molecular basis of requirement of receptor activator of nuclear factor kappaB signaling for interleukin 1-mediated osteoclastogenesis. J Biol Chem 287: 15728-15738.
49. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL (2005) IL-1 mediates TNF-induced osteoclastogenesis. The Journal of clinical investigation 115: 282-290. (Pubitemid 40385470)
50. McHugh KP, Hodivala-Dilke K, Zheng MH, Namba N, Lam J, et al. (2000) Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. The Journal of clinical investigation 105: 433-440. (Pubitemid 30127243)
51. Takeshita S, Kaji K, Kudo A (2000) Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J Bone Miner Res 15: 1477-1488. (Pubitemid 30484517)
52. Jules J, Zhang P, Ashley JW, Wei S, Shi Z, et al. (2012) Molecular basis of requirement of receptor activator of nuclear factor kappaB signaling for interleukin 1-mediated osteoclastogenesis. The Journal of biological chemistry 287: 15728-15738.
53. Chen W, Li YP (1998) Generation of mouse osteoclastogenic cell lines immortalized with SV40 large T antigen. J Bone Miner Res 13: 1112-1123. (Pubitemid 28311779)
54. Wan Y (2010) PPARgamma in bone homeostasis. Trends Endocrinol Metab 21: 722-728.
55. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, et al. (2013) PPARgamma signaling and metabolism: the good, the bad and the future. Nat Med 19: 557-566.
56. Sottile V, Seuwen K, Kneissel M (2004) Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcified tissue international 75: 329-337. (Pubitemid 40064235)
57. Grey A, Bolland M, Gamble G, Wattie D, Horne A, et al. (2007) The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. The Journal of clinical endocrinology and metabolism 92: 1305-1310. (Pubitemid 46556402)
58. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, et al. (2003) Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. The Journal of clinical investigation 111: 1221-1230. (Pubitemid 36519939) Diseases